Research Topics
Species | Alan SandlerSummaryAffiliation: Vanderbilt University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerAlan Sandler
Vanderbilt University, Nashville, TN, USA
N Engl J Med 355:2542-50. 2006..Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers...- A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology GroupLeora Horn
Department of Hematology Oncology, Vanderbilt University, Nashville, Tennessee, USA
J Thorac Oncol 4:527-33. 2009.... - Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinibAlan Sandler
Division of Hematology/Oncology, Vanderbilt University, Medical Center, Nashville, Tennessee, USA
Oncology (Williston Park) 17:17-22. 2003..The phase III BR.21 trial is assessing erlotinib monotherapy in advanced refractory non-small-cell lung cancer. Results of these phase II trials will soon be available... - Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer modelsJeffrey M Albert
Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Clin Cancer Res 13:3033-42. 2007..Ionizing radiation induces DNA strand breaks, suggesting that PARP-1 inhibition may sensitize tumor cells to radiation... - Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathwaysAlan Sandler
Vanderbilt Ingram Cancer Center, Nashville, Tennessee 37232 6307, USA
Clin Cancer Res 12:4421s-4425s. 2006..Encouraging antitumor activity and safety of erlotinib plus bevacizumab support further development of this combination for patients with advanced NSCLC. A randomized phase II trial has been completed, and a phase III trial is ongoing... - Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxelIldiko Csiki
Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA
Clin Cancer Res 11:6634-40. 2005..However, in light of the apparent survival prolongation in the subset with a marked decline in urinary PGE-M levels, further investigation of strategies designed to decrease PGE(2) synthesis in NSCLC seems warranted... - Bevacizumab in non small cell lung cancerAlan Sandler
Thoracic Oncology, Vanderbilt Ingram Cancer Center, Nashville, Tennessee 37232 6307, USA
Clin Cancer Res 13:s4613-6. 2007..Future and current directions include evaluation of bevacizumab in earlier stages of NSCLC, in SCLC, and in combination with other targeted agents, such as erlotinib... - A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancerLeora Horn
Vanderbilt Ingram Cancer Center, Nashville, TN, USA
Clin Lung Cancer 12:161-5. 2011..Secondary objectives included progression-free survival (PFS), overall survival, and toxicity findings... - Irinotecan plus cisplatin in small-cell lung cancerAlan Sandler
Division of Medical Oncology, Vanderbilt University Medical Center, Nashville, Tennessee 37232 5536, USA
Oncology (Williston Park) 16:39-43. 2002..This article will review the use of irinotecan in combination with cisplatin in patients with small-cell lung cancer... - Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancerJeffrey M Albert
Department of Radiation Oncology, Vanderbilt University, 1301 Medical Center Drive, B 902 The Vanderbilt Clinic, Nashville, TN 37232 5671, USA
Cancer Epidemiol Biomarkers Prev 16:1845-51. 2007..Previous studies have examined the prognostic value of clusterin expression in various malignancies. In the present study, we examined clusterin staining in tumors resected from patients with non-small cell lung cancer (NSCLC)... - Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancerLeora Horn
Vanderbilt Ingram Cancer Centre, Division of Hematology Oncology, Nashville, Tennessee, USA
Clin Cancer Res 15:5040-8. 2009..In this article we review clinical data for molecular-targeted therapies in NSCLC, with emphasis on EGFR inhibitors and antiangiogenic agents... - VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumabDavid P Carbone
Vanderbilt University Medical Center, 685 PRB, 2220 Pierce Avenue, Nashville, TN 37232, United States
Lung Cancer 69:337-40. 2010..We found that VeriStrat could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen... - Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancerCarolyn Cao
Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-5671, USA
Cancer Res 66:11409-15. 2006..Clinical trials are needed to determine the potential of this combination therapy in patients with locally advanced lung cancer... - State-of-the-art treatment for advanced non-small-cell lung cancerAlan Sandler
Division of Hematology and Oncology, Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA
Oncology (Williston Park) 17:15-22. 2003.... - Irinotecan therapy for small-cell lung cancerAlan Sandler
Vanderbilt University, Medical Center, Nashville, Tennessee 37232, USA
Oncology (Williston Park) 16:419-25, 428, 433; discussion 433-4, 437-8. 2002.... - Development of clinical trials in a cooperative group setting: the eastern cooperative oncology groupDavid M Dilts
Owen Graduate School of Management and Engineering Management Program, School of Engineering, Vanderbilt University, 401 21st Avenue South, Nashville, TN 37203, USA
Clin Cancer Res 14:3427-33. 2008..Calendar time was collected for each major process for each study in this set... - Lung cancer adjuvant therapyLeora Horn
Department of Medicine, University of Toronto, Toronto, ON, Canada
Cancer J 13:210-6. 2007..In this article, we review the rationale and evidence for neoadjuvant and adjuvant therapy with chemotherapy, radiation therapy, and combined modality therapy in patients with resected non-small cell lung cancer... - Chemotherapy and antiangiogenic agents in non-small-cell lung cancerLeora Horn
Department of Medicine, University of Toronto, ON, Canada
Clin Lung Cancer 8:S68-73. 2007..Future directions will include the use of these agents in combination with one another as well as in combination with chemotherapy and radiation therapy in patients with early-stage (IA-IIIB) disease... - Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancerRoy S Herbst
The M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 25:4743-50. 2007..A single-arm phase I and II study of bevacizumab plus erlotinib demonstrated encouraging efficacy, with a favorable safety profile... - Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancerNasser Hanna
Indiana University, Indianapolis, IN 46202, USA
J Clin Oncol 24:2038-43. 2006..Our trial was designed to determine if a modified weekly regimen of IP would provide superior survival with less toxicity than EP... - The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxibMary J Fidler
Rush University Medical Center, Chicago, Illinois 60612, USA
Clin Cancer Res 14:2088-94. 2008..With these observations, we designed a phase II trial to evaluate the efficacy and safety of erlotinib plus celecoxib in advanced NSCLC... - A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancerSumeet Bhatia
Indiana University, 535 Barnhill Drive Room 473, Indianapolis, IN 46202, USA
Lung Cancer 38:73-7. 2002..In conclusion, weekly gemcitabine with paclitaxel in patients with advanced NSCLC is an active regimen; however, toxicity and poor survival precludes the use of this regimen as an experimental arm on a future phase III study... - Comparison of four chemotherapy regimens for advanced non-small-cell lung cancerJoan H Schiller
University of Wisconsin Hospital and Clinics, Madison, USA
N Engl J Med 346:92-8. 2002..CONCLUSIONS: None of four chemotherapy regimens offered a significant advantage over the others in the treatment of advanced non-small-cell lung cancer... - Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II studyNasser Hanna
Department of Medicine, Indiana University, 535 Barnhill Drive, Room 473, Indianapolis, IN 46202, USA
Lung Cancer 35:293-7. 2002..In addition, treatment-related morbidity and mortality appears to be unacceptably high with the VIP regimen... - Lung cancer in the elderly: current and future chemotherapeutic optionsStuart Hinton
Indiana University School of Medicine, Indianapolis, Indiana, USA
Drugs Aging 19:365-75. 2002..Given the prevalence of the disease, future studies need to include an appropriate number of elderly patients with continued emphasis on quality of life in addition to survival... - Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC. A Hoosier Oncology Group (HOG) phase II studySumeet Bhatia
Department of Medicine, Indiana University, 535 Barnhill Drive Room 473, Indianapolis, IN 46202, USA
Lung Cancer 38:85-9. 2002..5 months, 45, and 17%, respectively. In conclusion, consolidation chemotherapy was associated with significant hematologic toxicity without an obvious improvement in survival in comparison to other studies utilizing chemoradiation alone... - Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancerVincent A Miller
Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Clin Oncol 21:2094-100. 2003..This pilot trial combined gefitinib with carboplatin and paclitaxel to define the toxicities of the combination and assess drug-drug interactions in untreated advanced NSCLC patients... - Ongoing and future trials of biologic therapies in lung cancerPaul A Bunn
University of Colorado Cancer Center, Denver, CO, USA
Lung Cancer 41:S175-86. 2003..Many new agents have been developed to attack these targets. This article describes current and proposed trials for these new targeted therapies in both small cell and non-small cell lung cancers... - An advance in small-cell lung cancer treatment--more or lessJanessa Laskin
J Natl Cancer Inst 95:1099-101. 2003 - Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trialMark G Kris
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and the Weill Medical College of Cornell University, New York, NY 10021, USA
JAMA 290:2149-58. 2003..04) and diarrhea (P =.006). CONCLUSIONS: Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy... - TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerRoy S Herbst
University of Texas M.D. Anderson Cancer Center, Houston, USA
J Clin Oncol 23:5892-9. 2005..Never smokers treated with erlotinib and chemotherapy seemed to experience an improvement in survival and will undergo further investigation in future randomized trials... - Angiogenesis inhibition in the treatment of lung cancerEverett Vokes
University of Chicago, Chicago, IL, USA
Clin Adv Hematol Oncol 4:1-10; quiz 11-2. 2006..Ongoing studies are continuing to investigate new agents and identify the patients most likely to benefit from antiangiogenic therapy... - Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancRoy S Herbst
Department of Thoracic/Head and Neck Medical Oncology, Biostatistics and Diagnostic Radiology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
J Clin Oncol 23:2544-55. 2005..6 months, with progression-free survival of 6.2 months. CONCLUSION: Encouraging antitumor activity and safety of A + T support further development of this combination for patients with advanced NSCLC and other solid tumors... - Angiogenesis and lung cancer: prognostic and therapeutic implicationsRoy S Herbst
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030 4009, USA
J Clin Oncol 23:3243-56. 2005.... - A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancyAlan Sandler
Department of Medicine, Section of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA
Clin Cancer Res 10:3265-72. 2004..The higher doses of zosuquidar were associated with maximal P-glycoprotein inhibition in natural killer cells. CONCLUSION: Zosuquidar can be safely coadministered with doxorubicin using a 48 h i.v. dosing schedule... - Clinical utility of EUS-guided fine-needle aspiration of mediastinal masses in the absence of known pulmonary malignancyBenedict M Devereaux
Indiana University Medical Center, Indianapolis, Indiana 46202, USA
Gastrointest Endosc 56:397-401. 2002..CONCLUSIONS: EUS-FNA is a minimally invasive technique that facilitates detection and tissue sampling of mediastinal masses. It is a safe procedure that can be performed with the patient under conscious sedation in an outpatient setting... - Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapiesRamaswamy Govindan
Washington University School of Medicine, St Louis, MO 63110, USA
J Clin Oncol 24:4848-54. 2006..To evaluate the effect of bexarotene on survival in patients with relapsed non-small-cell lung cancer (NSCLC)... - Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal functionAlain C Mita
Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, 78229, USA
J Clin Oncol 24:552-62. 2006..Additional studies are needed to define appropriate dosing for renally impaired patients receiving higher dose pemetrexed with vitamin supplementation... - Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597Gregory A Masters
Helen Graham Cancer Center, 4701 Ogletown Stanton Rd, Ste 2200, Newark, DE 19713, USA
J Clin Oncol 21:1550-5. 2003..The objective of this phase II trial was to investigate the activity of gemcitabine in patients with relapsed SCLC... - A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremitiesArno J Mundt
University of Chicago Medical Center, Chicago, Illinois, USA
Clin Cancer Res 10:5747-53. 2004..The objective of this study was to assess the tolerance of combining TNFerade and radiation therapy in patients with soft tissue sarcomas of the extremity... - Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungsGregory A Otterson
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
Clin Cancer Res 13:1246-52. 2007..To evaluate the toxicity profile of inhalational doxorubicin in patients with malignant disease in the lung... - Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancerChristopher J Sweeney
Indiana University Cancer Center, Indianapolis, IN, USA
Clin Cancer Res 12:536-42. 2006....